Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol

Reducing low-density lipoprotein cholesterol (LDL-C) levels is crucial to the prevention of atherosclerotic cardiovascular disease (ASCVD). However, many patients, especially those at very high ASCVD risk or with familial hypercholesterolemia (FH), do not achieve target LDL-C levels with statin mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Farzahna, Mansfield, Brett, Raal, Frederick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419884/
https://www.ncbi.nlm.nih.gov/pubmed/37568484
http://dx.doi.org/10.3390/jcm12155082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419884/
https://www.ncbi.nlm.nih.gov/pubmed/37568484
http://dx.doi.org/10.3390/jcm12155082

Ejemplares similares